Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26460758 | 0.93 | CYP1A2 (0.35) | CYP1A2ADORA2ACTSSCTSKMKNK1 | |
| SCHEMBL20209636 | 0.92 | ADORA2A (0.39) | CYP1A2ADORA2ACTSSCTSKMKNK1 | |
| SCHEMBL26460881 | 0.88 | CYP1A2 (0.35) | CYP1A2ADORA2ACTSSCTSKMKNK1 | |
| SCHEMBL26460818 | 0.85 | CYP1A2 (0.40) | CYP1A2ADORA2ACTSSCTSKSCN5A | |
| SCHEMBL26461634 | 0.76 | CTSS (0.32) | CYP1A2CTSSCTSK | |
| SCHEMBL20209633 | 0.73 | ADORA2A (0.41) | CYP1A2ADORA2AMKNK1MKNK2SCN5A | |
| SCHEMBL26462714 | 0.73 | AAK1 (0.34) | CYP1A2 | |
| SCHEMBL20190978 | 0.72 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL26462287 | 0.69 | AAK1 (0.34) | — | |
| SCHEMBL12909263 | 0.68 | AR (0.40) | SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | PRAXIS PRECISION MEDICINES, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | SCN1A, SCN3A, SCN2A | CYP1A2 3251/4885ADORA2A 3636/4885CTSS 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.